找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Histiocytic Disorders; Oussama Abla,Gritta Janka Book 2018 Springer International Publishing AG 2018 langerhans cell Histiocytosis.hemopha

[復制鏈接]
樓主: fungus
41#
發(fā)表于 2025-3-28 16:36:30 | 只看該作者
Hematopoietic Cell Transplantation and Novel Therapies in Hemophagocytic Lymphohistiocytosis HLH, HCT is essential for preventing future episodes of fatal HLH in patients with genetic predisposition to HLH. Survival with HCT has increased significantly in recent years with the adoption of reduced intensity conditioning (RIC) regimens. However, RIC treatment protocols carry their own distin
42#
發(fā)表于 2025-3-28 22:25:48 | 只看該作者
43#
發(fā)表于 2025-3-29 02:09:38 | 只看該作者
Biology and Genomics of LCH and Related Disordersnslocations that produce fusion proteins which activate . occur more frequently in ECD than in LCH. The presence of some of these activating mutations in circulating cells or in CD34+ bone marrow cells suggests that these diseases may arise from transforming events in early myeloid precursors. ICH c
44#
發(fā)表于 2025-3-29 05:59:33 | 只看該作者
Central Nervous System Langerhans Cell Histiocytosisnation. Biopsies of such lesions are rare. In the few published cases biopsied, variable pathologies are described with perivascular inflammatory changes, variable neuronal loss, demyelination, and gliosis, but are nondiagnostic for CD1a+/CD207+ LCH cells. Granulomatous LCH can be responsive to chem
45#
發(fā)表于 2025-3-29 10:26:28 | 只看該作者
First-Line Treatment of Pediatric Langerhans Cell Histiocytosisactivation rates. The effect of further prolongation is being studied in the current LCH-IV protocol of the Histiocyte Society. It is to be expected that in the (near) future, the use of BRAF and MEK inhibitors may be introduced in first-line therapy, especially for very high-risk patients. For thes
46#
發(fā)表于 2025-3-29 11:43:44 | 只看該作者
47#
發(fā)表于 2025-3-29 16:01:58 | 只看該作者
48#
發(fā)表于 2025-3-29 21:34:41 | 只看該作者
49#
發(fā)表于 2025-3-30 01:58:56 | 只看該作者
50#
發(fā)表于 2025-3-30 04:02:08 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-13 16:04
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復 返回頂部 返回列表
万载县| 金门县| 佳木斯市| 甘泉县| 西宁市| 托里县| 东丽区| 米脂县| 永和县| 盘锦市| 鹤庆县| 沧源| 平果县| 贡觉县| 开江县| 开平市| 大庆市| 兴安县| 建昌县| 准格尔旗| 繁峙县| 淳安县| 大余县| 民丰县| 兴仁县| 内乡县| 二连浩特市| 高密市| 澜沧| 遵化市| 浦城县| 雅安市| 德阳市| 昌平区| 通河县| 肥西县| 信丰县| 莱西市| 汝阳县| 永仁县| 海原县|